CLAIMS

1. A pharmaceutical composition comprising;

an immediate release component, wherein the immediate release component comprises from 2.5 g of γ-((*L*-valyl)oxy)butanoic acid to 7 g of γ-((*L*-valyl)oxy)butanoic acid; and

a modified release component, wherein the modified release component comprises from 7 g of γ-((*L*-valyl)oxy)butanoic acid to 15 g of γ-((*L*-valyl)oxy)butanoic acid.

2. The pharmaceutical composition of claim 1, wherein,

the immediate release component comprises from 10 wt% to 50 wt% of 4-((*L*-valyl)oxy)butanoic acid; and

the modified release component comprises from 50 wt% to 90 wt% of 4-((*L*-valyl)oxy)butanoic acid,

wherein wt% is based on the total weight of 4-((*L*-valyl)oxy)butanoic acid in the pharmaceutical composition.

3. The pharmaceutical composition of claim 1 or 2, wherein the immediate release component comprises a solution suitable for oral administration.

4. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises a solution comprising the immediate release component; and

the modified release component comprises a suspension of modified release microparticles suspended in the solution; and

the pharmaceutical composition is suitable for oral administration.

5. The pharmaceutical composition of claim 1, wherein the immediate release component comprises a plurality of immediate release microparticles.

6. The pharmaceutical composition of claim 5, wherein the immediate release microparticles comprise greater than 90 wt% of 4-((*L*-valyl)oxy)butanoic acid; and wt% is based on the total weight of the immediate release microparticles.

7. The pharmaceutical composition of claim 5, wherein the immediate release microparticles comprise:

from 95.0 wt% to 99.5 wt% of γ-((*L*-valyl)oxy)butanoic acid;

from 0.1 wt% to 2.0 wt% of a flow control agent; and

from 0.1 wt% to 1.0 wt% of a binder, wherein,

wt% is based on the total weight of the immediate release microparticles.

8. The pharmaceutical composition of claim 5, wherein the immediate release microparticles have a volume mean diameter D(4,3) from 200 μm to 500 μm.

9. The pharmaceutical composition of claim 1, wherein

the modified release component comprises modified release microparticles;

the modified release microparticles comprise a core and a modified release coating surrounding the core; and the core comprises greater than 90 wt% of 4-((*L*-valyl)oxy)butanoic acid, wherein wt% is based on the total weight of the core.

10. The pharmaceutical composition of claim 9, wherein the modified release microparticles comprise from 10 wt% to 35 wt% of the modified release coating; and wt% is based on the total weight of the modified release microparticles.

11. The pharmaceutical composition of claim 9, wherein,

the modified release microparticles have an average particle diameter from 150 μm to 350 μm; and

the average particle diameter is determined using laser diffraction or sieve analysis.

12. The pharmaceutical composition of claim 1, wherein

the immediate release component comprises immediate release microparticles; and

the modified release component comprises modified release microparticles.

13. The pharmaceutical composition of claim 1, wherein a weight ratio of γ-((*L*-valyl)oxy)butanoic acid in the immediate release component to γ-((*L*-valyl)oxy)butanoic acid in the modified release component is from 1:2 to 1:3.

14. The pharmaceutical composition of claim 1, wherein,

the immediate release component comprises from 20 wt% to 40 wt% of γ-((*L*-valyl)oxy)butanoic acid; and

the modified release component comprises form 60 wt% to 80 wt% of γ-((*L*-valyl)oxy)butanoic acid; and

wt% is based on the total weight of γ-((*L*-valyl)oxy)butanoic acid.

15. Use of a pharmaceutical composition of any one of claims 1 to 14 in the preparation of medicament for treating narcolepsy, excessive daytime sleepiness, cataplexy, excessive daytime

sleepiness associated with narcolepsy, excessive daytime sleepiness associated with Parkinson's disease, excessive daytime sleepiness associated with multiple sclerosis, cataplexy associated with narcolepsy, fatigue, fatigue associated with Parkinson's diseases, fatigue associated with multiple sclerosis, or fibromyalgia.